TY  - GEN 
AU  - Ruiz Villaverde, Ricardo
AU  - Rodríguez-Fernández Freire, Lourdes
AU  - Cebolla Verdugo, Marta
AU  - Prados Carmona, Alvaro
AU  - Hernández Montoya, Carlos
AU  - Armario Hita, José Carlos
AU  - Galán Gutiérrez, Manuel
A4  - Cirugía
A4  - Medicina
PY  - 2024
SN  - 20751729
UR  - http://hdl.handle.net/10498/33643
AB  - Introduction: Psoriasis, a chronic inflammatory skin disease, affects 2–10% of the population
globally. Bimekizumab (BMK), a monoclonal antibody targeting IL-17, is a dual inhibitor of
IL17 A and F that has shown efficacy in treating moderate to...
LA  - eng
PB  - MDPI
KW  - psoriasis
KW  - bimekizumab
KW  - biological therapy
TI  - Bimekizumab: Short-Term Effectiveness and Safety in Real Clinical Practice in Andalucia, Spain
DO  - 10.3390/life14030281
ER  -